HIV-DNA Dynamics in HIV Monoinfected or HIV/HCV Coinfected Patients — ViDyMoCo  

HIV Clinical Trial

Official title: Dynamics of Viral Reservoir in HIV-positive Patients With or Without HCV Coinfection in the Era of Direct-acting Antiviral and Antiretroviral Drugs

Status Recruiting

Clinical Trial Summary

New markers of viral activity are now under investigation. Aim of the study is to investigate the efficacy of new antiretroviral drugs by monitoring HIV-DNA dynamics in HIV-positive population. In HIV/HCV coinfected population, the study of HIV reservoir dynamics and the analysis of the prevalence of HCV resistance-associated mutations will help clinicians to improve the management of coinfected patients.

Clinical Trial Description

New markers of viral activity are now under investigation. Besides HIV-RNA and CD4 cells count, HIV-DNA is an emerging marker of viral reservoir, that seems to be associated with the risk of HIV-related diseases, especially in HCV coinfected patients. New antiretroviral drugs, particularly integrase inhibitors, are expected to decrease residual viremia and, consequently, viral reservoir. Monitoring of HIV-DNA dynamics during antiretroviral treatment could lead to a better management of HIV infected population.

Also, the role of HCV in influencing HIV natural history requires careful monitoring. In particular, with a broader use of direct acting antiretroviral, the analysis of prevalence of HCV resistance associated mutation will be more and more important to manage patients with treatment failure. ;

Related Conditions & MeSH terms

• HIV

• NCT number: NCT02836782
• Study type: Observational [Patient Registry]
• Source: Catholic University of the Sacred Heart
• Contact: Simona Di Giambenedetto, Researcher
• Phone: 0630155366
• Email: simona.digiambenedetto@unicatt.it
• Status: Recruiting
• Start date: April 2016
• Completion date: April 2025